What's new

EMEA-002924-PIP02-23

EMEA-002924-PIP02-23

Jun 6, 2025 - 17:40
 0
EMEA-002924-PIP02-23
EMEA-002924-PIP02-23
Read More

Tags:

Previous Article

NIH seeks comment on creation of first AI strategic plan, adds to tranche of AI ...

Next Article

Opinion/decision on a Paediatric investigation plan (PIP): Opdualag, nivolumab,R...

Related Posts

EMA workshop on primary efficacy endpoints for antivirals and monoclonal antibodies intended for the treatment of COVID-19 and influenza, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 June 2025, 13:00 (CEST) to 6 June 2025, 17:00 (CEST)

EMA workshop on primary efficacy endpoints for antivira...

May 13, 2025  0

Timetable: Type II variation and worksharing applicatio...

May 23, 2025  0

Human medicines European public assessment report (EPAR): Cholestagel, colesevelam, Date of authorisation: 09/03/2004, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 3, 2025  0